Medicaid coverage of medications to treat alcohol and opioid dependence
- PMID: 25921475
- DOI: 10.1016/j.jsat.2015.04.009
Medicaid coverage of medications to treat alcohol and opioid dependence
Abstract
Substance use disorders affect 12% of Medicaid beneficiaries. The prescription drug epidemic and growing need for treatment of alcohol and opioid dependence have refocused states' attention on their provision of substance use disorder treatment services, including medications. This study characterized how Medicaid programs cover these treatment medications. Data were from 2013 Medicaid pharmacy documents, 2011 and 2012 Medicaid state drug utilization records, and a 2013 American Society of Addiction Medicine survey. Results showed that only 13 state Medicaid programs included all medications approved for alcohol and opioid dependence on their preferred drug lists. The most commonly excluded were extended-release naltrexone (19 programs), acamprosate (19 programs), and methadone (20 programs). For combined buprenorphine-naloxone, 48 Medicaid programs required prior authorization, and 11 programs used 1- to 3-year lifetime treatment limits. Given the chronic nature of substance use disorders and the overwhelming evidence supporting ongoing coverage for many of these medications, states may want to reexamine substance use disorder benefits.
Keywords: Alcohol; Financing health care; Insurance coverage; Lifetime treatment limits; Opioid; Preferred drug lists.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.Drug Alcohol Depend. 2009 Jan 1;99(1-3):345-9. doi: 10.1016/j.drugalcdep.2008.07.018. Epub 2008 Sep 25. Drug Alcohol Depend. 2009. PMID: 18819759 Free PMC article.
-
Addiction pharmacotherapy 2000: new options, new challenges.J Psychoactive Drugs. 2000 Oct-Dec;32(4):371-8. doi: 10.1080/02791072.2000.10400238. J Psychoactive Drugs. 2000. PMID: 11210198 Review.
-
Pharmacotherapy for Substance Use Disorders.Med Clin North Am. 2016 Jul;100(4):891-910. doi: 10.1016/j.mcna.2016.03.011. Epub 2016 Apr 20. Med Clin North Am. 2016. PMID: 27235620 Review.
-
Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.Adv Ther. 2018 Apr;35(4):457-466. doi: 10.1007/s12325-018-0696-y. Epub 2018 Apr 6. Adv Ther. 2018. PMID: 29623562
-
Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.Subst Abus. 2016;37(1):63-9. doi: 10.1080/08897077.2015.1080208. Epub 2015 Nov 13. Subst Abus. 2016. PMID: 26566761 Free PMC article.
Cited by
-
Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21.Health Aff (Millwood). 2023 May;42(5):658-664. doi: 10.1377/hlthaff.2022.01513. Health Aff (Millwood). 2023. PMID: 37126752 Free PMC article.
-
Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019.Ann Med. 2023 Dec;55(1):514-520. doi: 10.1080/07853890.2023.2171107. Ann Med. 2023. PMID: 36724766 Free PMC article.
-
Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine.Subst Abus. 2022 Dec;43(1):1057-1071. doi: 10.1080/08897077.2022.2060424. Subst Abus. 2022. PMID: 35442178 Free PMC article.
-
Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients.Psychiatr Serv. 2021 Feb 1;72(2):225-226. doi: 10.1176/appi.ps.202000165. Epub 2020 Sep 10. Psychiatr Serv. 2021. PMID: 32907476 Free PMC article. No abstract available.
-
Outpatient care for opioid use disorder among the commercially insured: Use of medication and psychosocial treatment.J Subst Abuse Treat. 2020 Aug;115:108040. doi: 10.1016/j.jsat.2020.108040. Epub 2020 May 22. J Subst Abuse Treat. 2020. PMID: 32600627 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
